Vineet Laboratories
- P/E
- 64.74
Key Fundamentals
MicrocapPharmaceuticals & BiotechnologyHealthcarePrice-based figures as of · EPS basis: Standalone · TTM
- ROCE
- 8.49%
- Debt to Equity
- 0.99
- EPS (TTM)
- ₹0.58
- Book Value
- ₹23.75
- Market Cap
- —
- P/E (TTM)
- 64.74
- P/B
- 1.58
- ROE
- 3.68%
- Dividend Yield
- 2.77%
- EBITDA
- ₹8.48 Cr
- 52W High
- ₹43.50
- 52W Low
- ₹27.96
- Day Range
- ₹36.01 – ₹39.09
- Volume
- 53,360
Peer Comparison
Healthcare › Pharmaceuticals
| ₹1,773.40 | 38.81 | ₹4,29,049 Cr | 4.77 | 0.90% | 16.00% | 20.50% | ₹61,631 Cr | ₹10,987 Cr | |
| ₹10,037.50 | 91.10 | ₹2,65,269 Cr | 15.90 | 0.30% | 16.50% | 22.00% | ₹11,230 Cr | ₹2,925 Cr | |
| ₹4,738.50 | 78.61 | ₹1,77,061 Cr | 9.81 | 0.82% | 27.40% | 15.20% | ₹17,400 Cr | ₹2,099 Cr | |
| ₹1,188.10 | 26.44 | ₹1,25,446 Cr | 4.37 | 0.08% | 21.20% | 21.10% | ₹28,592 Cr | ₹4,593 Cr | |
| ₹2,323.80 | 114.81 | ₹1,25,228 Cr | 20.72 | 0.04% | 18.30% | 17.80% | ₹7,270 Cr | ₹1,090 Cr | |
| ₹1,374.00 | 35.59 | ₹1,14,543 Cr | 2.96 | 0.58% | 11.20% | 13.00% | ₹33,228 Cr | ₹3,184 Cr | |
| ₹1,402.00 | 33.59 | ₹1,12,454 Cr | 3.20 | 0.93% | 11.60% | 15.50% | ₹28,324 Cr | ₹3,356 Cr | |
| Vineet Laboratories (this company) | ₹37.55 | 64.74 | ₹70 Cr | 1.58 | 2.77% | 3.68% | 8.49% | ₹63 Cr | ₹1 Cr |
| Median 8 companies | ₹1,587.70 | 51.78 | ₹1,25,337 Cr | 4.57 | 0.70% | 16.25% | 16.65% | ₹22,862 Cr | ₹3,055 Cr |
Comparable companies in the same industry. Market cap, P/E and P/B use the latest price; other metrics are as reported in filings. A dash means the figure is not published for that company.
Tapetide Score
Data-driven rating, 0–100, as of . How it works →
Overall score
Data confidence 100/100
Category scores
- Quality
- 25
- Poor
- Returns, margins, earnings quality 22% weight
- Valuation
- 40
- Weak
- Cheap vs sector & own history 24% weight
- Growth
- 14
- Poor
- Sales & profit trajectory 9% weight
- Financial Health
- 25
- Poor
- Solvency, leverage, coverage 9% weight
- Momentum
- 60
- Good
- Trend strength, vol-adjusted 12% weight
- Ownership
- 45
- Weak
- FII/DII/promoter flows 24% weight
The Tapetide Score is data analysis, not investment advice. Tapetide is not a SEBI-registered research analyst or investment adviser.
Key Insights
No strengths listed
Weaknesses
6- Company has low interest coverage ratio.
- The company has delivered a poor sales growth of -24.6% over past five years.
- Promoter holding is low: 5.98%
- Company has a low return on equity of -22.7% over last 3 years.
- Promoter holding has decreased over last 3 years: -32.7%
- Working capital days have increased from 26.7 days to 89.0 days
Technical Indicators
| Group | Signal | Bearish | Neutral | Bullish |
|---|---|---|---|---|
| Overall | Strong Bullish | 2 | 7 | 10 |
| Oscillators | Bearish | 2 | 7 | 0 |
| Moving Averages | Strong Bullish | 0 | 0 | 10 |
Oscillators
Bearish
Overall
Strong Bullish
Moving Averages
Strong Bullish
Key readings
- RSI (14)
- 52.30
- Neutral
- MACD (12,26,9)
- −0.01
- Bearish
- SMA (50)
- 37.04
- Bullish
- SMA (200)
- 34.90
- Bullish
As of
Growth Rate
From the financial statements below. 5Y, 3Y: compound annual growth to Mar 2026; 1Y: fiscal year to Mar 2026 against Mar 2025.
Revenue
| 5Y | −24.58% |
|---|---|
| 3Y | −34.59% |
| 1Y | −20.80% |
Net profit
| 5Y | −9.01% |
|---|---|
| 3Y | −3.88% |
| 1Y | Turned to profit |
Operating cash flow
| 5Y | Turned negative |
|---|---|
| 3Y | Outflow widened by ₹2.41 Cr |
| 1Y | Turned negative |
Operating margin· change in pp
| 5Y | +10.94 pp |
|---|---|
| 3Y | +10.68 pp |
| 1Y | +36.00 pp |
Trailing twelve months: The last four quarters end with the latest fiscal year, which the 1Y column covers.
Revenue by year
| Mar 2020 | ₹0.00 Cr |
|---|---|
| Mar 2021 | ₹243 Cr |
| Mar 2022 | ₹191 Cr |
| Mar 2023 | ₹212 Cr |
| Mar 2024 | ₹151 Cr |
| Mar 2025 | ₹75.00 Cr |
| Mar 2026 | ₹59.40 Cr |
Net profit by year
| Mar 2020 | −₹0.01 Cr |
|---|---|
| Mar 2021 | ₹1.78 Cr |
| Mar 2022 | ₹6.64 Cr |
| Mar 2023 | ₹1.25 Cr |
| Mar 2024 | ₹1.03 Cr |
| Mar 2025 | −₹20.19 Cr |
| Mar 2026 | ₹1.11 Cr |
Quarterly Results
₹ CrResults for the period ended Jun 2026 were due by 14 Aug 2026 and are not in this table yet.
| Particulars | Mar 2023 | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 57.2 | 37.52 | 43.37 | 32.65 | 37.05 | 23.86 | 18.96 | 18.1 | 14.08 | 7.44 | 17.42 | 15.65 | 18.89 |
| Expenses | 51.39 | 37.26 | 39.2 | 33.29 | 33.63 | 24.65 | 19.27 | 22.23 | 25.12 | 7.13 | 14.24 | 13.17 | 16.4 |
| Operating Profit | 5.81 | 0.26 | 4.17 | −0.64 | 3.42 | −0.79 | −0.31 | −4.13 | −11.04 | 0.31 | 3.18 | 2.48 | 2.49 |
| OPM % | 10.16% | 0.69% | 9.61% | −1.96% | 9.23% | −3.31% | −1.64% | −22.82% | −78.41% | 4.17% | 18.25% | 15.85% | 13.18% |
| Other Income | 0.03 | 0.03 | 0.01 | 0.01 | 0.41 | 0.37 | 0.2 | 0.03 | 1.38 | 0.02 | 0.01 | 0.05 | 0.03 |
| Interest | 0.37 | 0.96 | 1.02 | 1.08 | 1.72 | 1.14 | 0.99 | 0.95 | 0.9 | 0.61 | 2.19 | 1.09 | 0.99 |
| Depreciation | 0.62 | 0.61 | 0.61 | 0.63 | 0.67 | 0.61 | 0.62 | 0.62 | 0.66 | 0.63 | 0.63 | 0.63 | 0.54 |
| PBT | 4.85 | −1.28 | 2.54 | −2.33 | 1.43 | −2.17 | −1.71 | −5.67 | −11.22 | −0.91 | 0.37 | 0.82 | 0.99 |
| Tax % | 26.8% | −2.34% | 4.71% | −11.11% | −34.03% | −1.84% | 6.98% | 0.53% | −6.24% | −4.4% | −8.11% | −3.7% | 27.27% |
| Net Profit | 3.55 | −1.25 | 2.42 | −2.07 | 1.92 | −2.13 | −1.83 | −5.71 | −10.53 | −0.87 | 0.4 | 0.85 | 0.73 |
| EPS (₹) | 1.85 | −0.65 | 1.26 | −1.08 | 1 | −1.11 | −0.95 | −2.97 | −5.48 | −0.45 | 0.21 | 0.44 | 0.38 |
Profit & Loss
₹ Cr| Particulars | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|
| Sales | 0 | 243 | 191 | 212 | 151 | 75 | 59.4 |
| Expenses | 0.01 | 235 | 178 | 205 | 143 | 91.28 | 50.91 |
| Operating Profit | −0.01 | 8.15 | 13.16 | 7.66 | 7.2 | −16.28 | 8.49 |
| OPM % | — | 3.35% | 6.89% | 3.61% | 4.78% | −21.71% | 14.29% |
| Other Income | 0 | 0.39 | 0.29 | 0.12 | 0.46 | 1.99 | 0.1 |
| Interest | 0 | 2.67 | 2.09 | 3.38 | 4.78 | 3.98 | 4.89 |
| Depreciation | 0 | 1.81 | 2.02 | 2.37 | 2.52 | 2.5 | 2.41 |
| PBT | −0.01 | 4.06 | 9.34 | 2.03 | 0.36 | −20.77 | 1.28 |
| Tax % | 0% | 56.16% | 28.91% | 38.42% | −183.33% | −2.79% | 13.18% |
| Net Profit | −0.01 | 1.78 | 6.64 | 1.25 | 1.03 | −20.19 | 1.11 |
| EPS (₹) | −0.11 | 0.93 | 3.46 | 0.65 | 0.54 | −10.52 | 0.58 |
| Div. Payout % | 0% | 0% | 13.89% | 0% | 0% | 0% | 0% |
Balance Sheet
₹ Cr| Particulars | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|
| Equity Capital | 0.41 | 9.22 | 9.22 | 9.22 | 9.22 | 9.22 | 19.21 |
| Reserves | −0.01 | 17.4 | 24 | 24.46 | 25.51 | 5.43 | 26.4 |
| Borrowings | 0 | 12.48 | 26.51 | 31.09 | 44.3 | 40.05 | 45.33 |
| Other Liabilities | 0 | 69.64 | 73.59 | 51.08 | 37.84 | 39.84 | 33.84 |
| Total Liabilities | 0.4 | 109 | 133 | 116 | 117 | 94.54 | 125 |
| Fixed Assets | 0 | 19.67 | 21.38 | 26.65 | 26.92 | 25.46 | 24.24 |
| CWIP | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Investments | 0 | 0.12 | 0.14 | 0.13 | 0.18 | 0.21 | 0.19 |
| Other Assets | 0.4 | 88.95 | 112 | 89.07 | 89.77 | 68.87 | 100 |
| Total Assets | 0.4 | 109 | 133 | 116 | 117 | 94.54 | 125 |
Cash Flow
₹ Cr| Particulars | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|
| Operating | 0 | 27.49 | 7.63 | −9.62 | −6.61 | 11.49 | −12.03 |
| Investing | 0 | −7.81 | −3.68 | −6.69 | −2.22 | −3.18 | −1.11 |
| Financing | 0 | 18.62 | 11.96 | 0.27 | 8.43 | −8.23 | 29.74 |
| Net Cash Flow | 0 | 38.3 | 15.91 | −16.03 | −0.4 | 0.08 | 16.6 |
| Free Cash Flow | 0 | 27.49 | 7.63 | −17.25 | −9.4 | 10.44 | −13.23 |
| CFO/OP | 0 | 327 | 82 | −87 | −88 | −71 | −144 |
Ratios
| Particulars | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|
| Debtor Days | — | 64.03 | 69.14 | 60.45 | 76.59 | 64.48 | 70.05 |
| Inventory Days | — | 73.12 | 109 | 97.79 | 158 | 260 | 606 |
| Days Payable | — | 114 | 161 | 73.9 | 103 | 175 | 240 |
| Cash Conversion Cycle | — | 23.07 | 17.13 | 84.34 | 131 | 150 | 437 |
| Working Capital Days | — | 14.41 | −19.46 | 20.63 | 28.48 | −37.28 | 88.98 |
| ROCE % | — | 34.08% | 23.13% | 8.69% | 6.65% | −27.95% | 8.49% |
Insights
BetaAI-extracted from concalls & annual reports · figures as reported, with sources
Log in to view Vineet Laboratories insights
63 extracted metrics across FY20–FY26.
Documents
- 29 Aug 2026
- 25 Aug 2026
Frequently Asked Questions about Vineet Laboratories
What does Vineet Laboratories Ltd do?
Where is Vineet Laboratories Ltd (VINEETLAB) listed?
Which sector does Vineet Laboratories Ltd belong to?
What is the PE ratio of Vineet Laboratories Ltd?
What is the 52-week high and low of Vineet Laboratories Ltd?
Does Vineet Laboratories Ltd pay dividends?
What is the Return on Equity (ROE) of Vineet Laboratories Ltd?
Company Information
Incorporated in 2003, Vineet Laboratories Ltd is in designing, developing, manufacturing of API Intermediates and Bulk Drugs
For AI agents and developers
Reading this as an AI agent, LLM or automated pipeline? Every page on Tapetide is also published as clean Markdown — no navigation, no scripts, just the data. Fetch https://tapetide.com/stocks/VINEETLAB.md for Vineet Laboratories Ltd: dated key facts, then this page's sections in order: latest price, key fundamentals, peer comparison, the Tapetide Score, technical indicators, analyst ratings, growth rates, analyst forecasts, the AI analysis and news digest (labelled as AI-generated), financial statements, shareholding pattern, documents and the FAQ.
Append .md to any Tapetide URL for
the same treatment. A full index of what we publish is at /llms.txt and /llms-full.txt. For
live, structured queries instead of documents, use our Indian stock market MCP server.